May 02, 2012, 07.05 PM | Source: CNBC-TV18
D D Sharma of Risk Capital Advisors is of the view that one should buy Biocon.
Sharma told CNBC-Awaaz, "One can accumulate Biocon with a stoploss of Rs 229. The stock can touch level of Rs 255 in medium term."
The company touched its 52-week high Rs 382.00 and 52-week low Rs 225.75 on 20 Jul, 2011 and 27 Apr, 2012, respectively.
Currently, it is trading -37.72% below its 52-week high and 5.38% above its 52-week low.
The biosimilar product, which is developed and man
The company plans to invest USD 100 million (aroun
Of USD 200 million capex, USD 100 million will go
The most important news that everyone will be trac